Top Headlines and Trials from 2016: Time for Change?

Dr. Katelyn Halpape, BSP, PharmD, ACPR
Clinical Pharmacy Specialist – Neurosciences, Vancouver General Hospital
This presentation will review the key studies and headlines from 2016 and how we can apply this information to practice.

Trials Reviewed:
HOPE-3 (Cholesterol & BP Lowering)
EMPA-REG (Type 2 Diabetes)
LEADER (Type 2 Diabetes)
ATTACH-II (Intracranial Hemorrhage)

Handout

Let’s Explore Dyslipidemia Guidelines, Etc.

Arden Barry, BSc, BSc(Pharm), PharmD, ACPR Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services; Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia; Associate Member, Department of Family Practice, Faculty of Medicine, University of British Columbia

The treatment of dyslipidemia is controversial despite a plethora of available published evidence. This has led to the development of multiple dyslipidemia guidelines— while these documents differ with respect philosophy and complexity, they are more similar than they are different. This presentation aims to explore three recently published dyslipidemia guidelines with the goal of deriving a few pragmatic considerations that participants can apply in practice.

Handout: https://cshp-bc.com/events/handouts/2016/island/CSHP-BC%20VIEE_Barry_Dyslipidemia%20Handout.pdf

Managing NSTE-ACS: One Beat at a Time

Amy Nunley, BScPh, ACPR

Review of medications used to manage NSTEACS.

Objectives:

Describe at least 4 risk factors for NSTE-ACS

List at least 3 medications that have mortality benefit after NSTE-ACS

List target doses and monitoring parameters for each of:

  • Antiplatelets (Acetylsalicylic Acid [ASA], clopidogrel, ticagrelor)
  • ACE-inhibitors
  • Beta-blockers
  • Statins

Handout

Review of the updated Canadian Cardiovascular Society guidelines for the management of dyslipidemia

Dr. Arden Barry, BSc, BScPharm, PharmD, ACPR

Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services

Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia

Objectives:

Identify recently published guidelines for the treatment of dyslipidemia

Review key clinical trials in the management of dyslipidemia published since 2012

Review the key recommendaEons relevant to pharmacists from the (to be published) updated Canadian Cardiovascular Society guidelines for the management of dyslipidemia.

Handout